Coyne KS, Sexton CC, Vats V, Thompson C, Kopp ZS, Milsom I. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology. 2011;77(5):1081–7.

Article  PubMed  Google Scholar 

Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327–36.

Article  CAS  PubMed  Google Scholar 

Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. American Urological Association; 2019.

Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2009;15(9):728–40.

PubMed  Google Scholar 

Ali M, Grogan S, Powell S, et al. Qualitative analysis of factors influencing patient persistence and adherence to prescribed overactive bladder medication in UK primary care. Adv Ther. 2019;36(11):3110–22.

Article  PubMed  PubMed Central  Google Scholar 

Benner JS, Nichol MB, Rovner ES, et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int. 2010;105(9):1276–82.

Article  PubMed  Google Scholar 

Diokno AC, Sand PK, Macdiarmid S, Shah R, Armstrong RB. Perceptions and behaviours of women with bladder control problems. Fam Pract. 2006;23(5):568–77.

Article  PubMed  Google Scholar 

Kinjo M, Sekiguchi Y, Yoshimura Y, Nutahara K. Long-term persistence with mirabegron versus solifenacin in women with overactive bladder: prospective, randomized trial. Low Urin Tract Symptoms. 2018;10(2):148–52.

Article  CAS  PubMed  Google Scholar 

Soda T, Tashiro Y, Koike S, Ikeuchi R, Okada T. Overactive bladder medication: persistence, drug switching, and reinitiation. Neurourol Urodyn. 2020;39(8):2527–34.

Article  PubMed  Google Scholar 

Anger JT, Nissim HA, Le TX, et al. Women’s experience with severe overactive bladder symptoms and treatment: insight revealed from patient focus groups. Neurourol Urodyn. 2011;30(7):1295–9.

Article  PubMed  PubMed Central  Google Scholar 

Witticke D, Seidling HM, Klimm HD, Haefeli WE. Do we prescribe what patients prefer? Pilot study to assess patient preferences for medication regimen characteristics. Patient Prefer Adherence. 2012;6:679–84.

PubMed  PubMed Central  Google Scholar 

Carlson KV, Rovner ES, Nair KV, Deal AS, Kristy RM, Hairston JC. Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: findings from the PERSPECTIVE registry study. Low Urin Tract Symptoms. 2021;13(4):425–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Coyne KS, Payne C, Bhattacharyya SK, et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health. 2004;7(4):455–63.

Article  PubMed  Google Scholar 

Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008;101(11):1388–95.

Article  PubMed  Google Scholar 

Melotti IGR, Juliato CRT, Tanaka M, Riccetto CLZ. Severe depression and anxiety in women with overactive bladder. Neurourol Urodyn. 2018;37(1):223–8.

Article  PubMed  Google Scholar 

Yehoshua A, Chancellor M, Vasavada S, et al. Health resource utilization and cost for patients with incontinent overactive bladder treated with anticholinergics. J Manag Care Spec Pharm. 2016;22(4):406–13.

PubMed  Google Scholar 

Lua LL, Pathak P, Dandolu V. Comparing anticholinergic persistence and adherence profiles in overactive bladder patients based on gender, obesity, and major anticholinergic agents. Neurourol Urodyn. 2017;36(8):2123–31.

Article  CAS  PubMed  Google Scholar 

Chancellor MB, Migliaccio-Walle K, Bramley TJ, Chaudhari SL, Corbell C, Globe D. Long-term patterns of use and treatment failure with anticholinergic agents for overactive bladder. Clin Ther. 2013;35(11):1744–51.

Article  CAS  PubMed  Google Scholar 

Song YS, Lee HY, Park JJ, Kim JH. Persistence and adherence of anticholinergics and beta-3 agonist for the treatment of overactive bladder: systematic review and meta-analysis, and network meta-analysis. J Urol. 2021;205(6):1595–604.

Article  PubMed  Google Scholar 

Yeowell G, Smith P, Nazir J, Hakimi Z, Siddiqui E, Fatoye F. Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review. BMJ Open. 2018;8(11): e021889.

Article  PubMed  PubMed Central  Google Scholar 

Ivanova JI, Hayes-Larson E, Sorg RA, Birnbaum HG, Berner T. Healthcare resource use and costs of privately insured patients who switch, discontinue, or persist on anti-muscarinic therapy for overactive bladder. J Med Econ. 2014;17(10):741–50.

Article  PubMed  Google Scholar 

Balkrishnan R, Bhosle MJ, Camacho FT, Anderson RT. Predictors of medication adherence and associated health care costs in an older population with overactive bladder syndrome: a longitudinal cohort study. J Urol. 2006;175(3 Pt 1):1067–72.

Article  PubMed  Google Scholar 

Sicras-Mainar A, Navarro-Artieda R, Ruiz-Torrejon A, Saez-Zafra M, Coll-de Tuero G. Impact of loss of work productivity in patients with overactive bladder treated with antimuscarinics in Spain: study in routine clinical practice conditions. Clin Drug Investig. 2015;35(12):795–805.

Article  CAS  PubMed  Google Scholar 

GEMTESA® (vibegron). Full Prescribing Information. Irvine, CA: 2020.

Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN Jr. International phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR. J Urol. 2020;204(2):316–24.

Article  PubMed  Google Scholar 

Frankel J, Varano S, Staskin D, Shortino D, Jankowich R, Mudd PN Jr. Vibegron improves quality-of-life measures in patients with overactive bladder: patient-reported outcomes from the EMPOWUR study. Int J Clin Pract. 2021;75(5): e13937.

Article  PubMed  Google Scholar 

Pharmacy Quality Alliance. PQA measure overview. Alexandria, VA: 2023.

Sussman D, Yehoshua A, Kowalski J, et al. Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real-world claims data analysis. Int J Clin Pract. 2017;71(3–4): e12824.

Article  PubMed  Google Scholar 

Wagg A, Franks B, Ramos B, Berner T. Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: early experience in Canada. Can Urol Assoc J. 2015;9(9–10):343–50.

Article  PubMed  PubMed Central  Google Scholar 

Mukai S, Nomi M, Yamada S, Yanagiuchi A, Sengoku A. The 1-year continuation rate and discontinuation factors of vibegron and mirabegron: a retrospective comparative study in a rehabilitation hospital in Japan. Low Urin Tract Symptoms. 2021;13(4):448–55.

Article  CAS  PubMed  Google Scholar 

Chapple CR, Nazir J, Hakimi Z, et al. Persistence and adherence with mirabegron versus antimuscarinic agents in patients with overactive bladder: a retrospective observational study in UK clinical practice. Eur Urol. 2017;72(3):389–99.

Article  CAS  PubMed  Google Scholar 

Perk S, Wielage RC, Campbell NL, et al. Estimated budget impact of increased use of mirabegron, a novel treatment for overactive bladder. J Manag Care Spec Pharm. 2016;22(9):1072–84.

PubMed  Google Scholar 

Chen JV, Klein TM, Nesheim J, Mudd PN Jr. Cost-effectiveness of vibegron for the treatment of overactive bladder in the United States. J Med Econ. 2022;25(1):1092–100.

Article  PubMed  Google Scholar 

Happe LE, Clark D, Holliday E, Young T. A systematic literature review assessing the directional impact of managed care formulary restrictions on medication adherence, clinical outcomes, economic outcomes, and health care resource utilization. J Manag Care Spec Pharm. 2014;20(7):677–84.

PubMed  Google Scholar 

Karlsson SA, Hero C, Eliasson B, et al. Refill adherence and persistence to lipid-lowering medicines in patients with type 2 diabetes: a nation-wide register-based study. Pharmacoepidemiol Drug Saf. 2017;26(10):1220–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bogart M, Stanford RH, Laliberté F, Germain G, Wu JW, Duh MS. Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population. Int J Chron Obstruct Pulmon Dis. 2019;14:343–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zeber JE, Manias E, Williams AF, et al. A systematic literature review of psychosocial and behavioral factors associated with initial medication adherence: a report of the ISPOR Medication Adherence & Persistence Special Interest Group. Value Health. 2013;16(5):891–900.

Article  PubMed  Google Scholar